Management of Supraventricular Tachycardia in Patients with Chronic Kidney Disease

Introduction to Treatment Guidelines

The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines recommend alternative agents in patients with significant comorbidities like advanced kidney disease 1, 2

The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines recommend continuing beta-blocker therapy as first-line therapy for SVT (Class I recommendation) 1, 2
Non-dihydropyridine calcium channel blockers, such as diltiazem or verapamil, can be considered as alternatives (Class I recommendation) 1
Sotalol or dofetilide may be reasonable alternatives (Class IIb recommendation) but require careful monitoring and dose adjustment in renal impairment 1
Amiodarone may be considered when other agents are ineffective or contraindicated (Class IIb recommendation) 1

The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines recommend catheter ablation as first-line therapy for patients with SVT, particularly those with advanced kidney disease (Class I recommendation) 1, 2
Catheter ablation provides definitive treatment without ongoing medication-related risks and has high success rates (>90%) for SVT ablation with low complication rates 1

Regular ECG monitoring for QRS prolongation and PR interval changes is recommended for patients on pharmacological therapy
Monitoring of renal function and assessment for signs of drug toxicity are also recommended
Evaluation of SVT burden and symptom control is necessary to adjust treatment as needed 1